Home / Psoriasis

Psoriasis

Janssen Reports Top-Line Phase 3 Results for Tremfya in Adults with Active Psoriatic Arthritis

HORSHAM, Pa.–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson today announced top-line results from the Phase 3 DISCOVER 1 and 2 studies, which evaluated the efficacy and safety of guselkumab compared to placebo in adult patients with active moderate to severe psoriatic arthritis (PsA). Both studies met their primary …

Read More »

First-of-its-Kind Data Shows Efficacy and Safety of Novartis’ Cosentyx in All Key Manifestations of Psoriatic Arthritis

Basel, June 12, 2019 – Novartis, a leader in rheumatology and immuno-dermatology, today announced new data from the MAXIMISE trial evaluating the efficacy and safety of Cosentyx (secukinumab) in the management of axial manifestations of psoriatic arthritis (PsA). The ongoing 52-week Phase IIIb trial met both its primary and key secondary …

Read More »

FDA Approves Sorilux Foam for Treatment of Plaque Psoriasis in Patients 12 Years and Older

ADELAIDE, Australia, May 22, 2019 /PRNewswire/ — Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that the US Food and Drug Administration (FDA) has approved SORILUX® (calcipotriene) Foam, 0.005% in adolescents. SORILUX is now approved for treating plaque psoriasis of the scalp and body in patients aged 12 …

Read More »

FDA Approves Samsung Bioepis’ Eticovo, a Biosimilar to Enbrel

INCHEON, Korea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved ETICOVO™ (etanercept-ykro), a biosimilar referencing ENBREL® (etanercept), across all eligible indications for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis and polyarticular juvenile idiopathic arthritis. ETICOVO™ is Samsung Bioepis’ second …

Read More »

New Data Show that Leo Pharma’s Kyntheum Sustains PASI 100 Scores Longer than Ustekinumab for Patients with Moderate-to-Severe Plaque Psoriasis

BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma A/S, a global leader in medical dermatology, today announced that new data presented this week at the 6th Congress of the Skin Inflammation and Psoriasis International Network (SPIN) in Paris demonstrate that more patients with moderate-to-severe psoriasis who received treatment with brodalumab maintained a PASI (Psoriasis …

Read More »

FDA Approves AbbVie’s Skyrizi for Treatment of Moderate-to-Severe Plaque Psoriasis

NORTH CHICAGO, Ill., April 23, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved SKYRIZI™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.3 In …

Read More »

LEO Pharma and Research Project BIOMAP: Towards Personalized Medicine for Inflammatory Skin Diseases

BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma, a global leader in medical dermatology and BIOMAP, a EU-funded research project (Biomarkers in Atopic Dermatitis and Psoriasis), today announced that BIOMAP kicks off its activities with the aim of improving the lives of patients affected by the two most common inflammatory skin conditions. Addressing key …

Read More »

Novartis’ Cosentyx Shows Superior Improvements in Psoriasis Patients’ Quality of Life Versus Janssen’s Stelara

Basel, March 5, 2019 – Novartis, a global leader in immuno-dermatology and rheumatology, announced today additional results from the head-to-head CLARITY study demonstrating the superiority of Cosentyx® (secukinumab) compared to Stelara®* (ustekinumab) in delivering specific quality of life (QoL) aspects in adults with moderate-to-severe plaque psoriasis at 16 weeks. New CLARITY data show over …

Read More »

FDA Approves Janssen’s Tremfya One-Press Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis

HORSHAM, PENNSYLVANIA, February 27, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis. TREMFYA® (guselkumab) is the first FDA-approved medication of its kind to offer the One-Press patient-controlled …

Read More »

Novartis Data Show Psoriasis Patients Treated with Cosentyx Reported Improvements in Quality of Life Measures as Early as Week 4

EAST HANOVER, N.J., Jan. 28, 2019 /PRNewswire/ — Novartis announced today results from a pooled analysis of four Phase 3 clinical trials demonstrating patients with moderate-to-severe plaque psoriasis (PsO) treated with Cosentyx® (secukinumab) 300 mg reported improvements in mobility, self-care, and usual activities components of the EQ-5D-3L questionnaire as early …

Read More »